AKRO Akero Therapeutics, Inc.

5d ago, source: Seeking Alpha

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product ...

Akero Therapeutics' Stock Is Soaring Monday - Here's Why

1mon ago, source: Hosted on MSN

Akero Therapeutics Inc (NASDAQ:AKRO) shares are trading higher after the company released preliminary topline week 96 results from HARMONY, a Phase 2b study of its lead product candidate ...

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

14d ago, source: Stockhouse

NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ ...

Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study

1mon ago, source: Nasdaq

Akero Therapeutics, Inc. AKRO announced a statistically significant histological improvement in the primary endpoint of its mid-stage study, evaluating the efficacy and safety of efruxifermin ...

Akero Therapeutics, Inc.

1mon ago, source: CNN

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin ...

Akero Therapeutics Inc AKRO

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Akero Therapeutics Inc.

28d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...